SWOG clinical trial number
S9713

A Phase II Trial of Cisplatin/Etoposide and Concurrent, Radiotherapy Followed by Paclitaxel/Carboplatin Consolidation For Limited Stage Small Cell Lung Cancer

Closed
Phase
Accrual
100%
Published
Abbreviated Title
CDDP+VP-16+RT -> Taxol/Carbo in SCLC
Activated
07/01/1998
Closed
08/01/1999

Research committees

Lung Cancer

Publication Information Expand/Collapse

2004

Phase II trial of cisplatin/etoposide and concurrent radiotherapy followed by paclitaxel/carboplatin consolidation for limited small-cell lung cancer: Southwest Oncology Group 9713

MJ Edelman;K Chansky;LE Gaspar;B Leigh;GR Weiss;SA Taylor;J Crowley;R Livingston;DR Gandara Journal of Clinical Oncology 22(1):127-132

2002

Phase II (SWOG 9713) trial of cisplatin/etoposide (PE) and concurrent radiotherapy (XRT) followed by paclitaxel/carboplatin (TC) consolidation for limited small cell lung cancer (LSCLC)

MJ Edelman;K Chansky;B Leigh;J Crowley;DR Gandara Proc of the American Society of Clinical Oncology 21:303a(#1210)

Other Clinical Trials

SWOG Clinical Trial Number
S2409

PRISM: PRecIsion in SCLC via a Multicohort Study: Randomized Phase II studies evaluating maintenance Durvalumab with or without Biomarker-Directed Therapy for Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Research Committee(s)
Lung Cancer
Activated
09/08/2025
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
CTSU/EA5231

A Randomized Phase III Trial of Checkpoint Blockade in Lung Cance3r Patients in the Adjuvant Setting Based on Pathologic Response Following Neoadjuvant Therapy (CLEAR)
Research Committee(s)
Lung Cancer
Activated
06/13/2025
Open
Phase
SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)
Research Committee(s)
Lung Cancer
Symptom Management and Survivorship
Activated
03/14/2025
Accrual
2%
Open
Phase